Management of BCG failures in non-muscle-invasive bladder cancer

Korean Journal of Urology

Volumn 50, Issue 11, 2009, Pages 1037-1047

  Han, Kyung Seok ^a   Hong, Sung Joon ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Bacillus Calmette Guerin; Cystectomy; Intravesical therapy; Treatment failure; Urinary bladder neoplasms

Indexed keywords

ALPHA INTERFERON; AMINOLEVULINIC ACID; ANTINEOPLASTIC METAL COMPLEX; BCG VACCINE; BIOLOGICAL MARKER; CD83 ANTIGEN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; INTERLEUKIN 8; KI 67 ANTIGEN; MITOMYCIN C; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA; VALRUBICIN;

BLADDER CANCER; BLADDER IRRITATION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER RESISTANCE; CANCER STAGING; CANCER SURGERY; CLINICAL PRACTICE; CLINICAL TRIAL; CYSTECTOMY; CYSTITIS; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEMODYNAMICS; HUMAN; HYPERTHERMIC THERAPY; HYPOTENSION; LOW DRUG DOSE; MONOTHERAPY; NON MUSCLE INVASIVE BLADDER CANCER; PHOTODYNAMIC THERAPY; POSTOPERATIVE COMPLICATION; PROGNOSIS; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TACHYCARDIA; TRANSURETHRAL RESECTION; TUMOR ASSOCIATED LEUKOCYTE; UNSPECIFIED SIDE EFFECT;

EID: 72849146884     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2009.50.11.1037     Document Type: Review

References (75)

1. Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother 2007;61:299-305. (Pubitemid 47189735)
2. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 1976;116:180-183
3. Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K, et al. A systematic review of intravesical bacillus Calmette- Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88:209-216 (Pubitemid 32863039)
4. Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006;67:1216-1223
5. Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette- Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169:90-95
6. Hong SJ, Choi HY, Ahn HJ, Kim CS, Yang WJ. Effect of intravesical high dose epirubicin versus bacillus Calmette- Guerin instillation on the recurrence and progression of superficial bladder cancer: a prospective, multicenter study. Korean J Urol 2005;46:677-682
7. Park JW, Park CH, Kim CI. Superficial bladder carcinoma treated with Bacillus Calmette-Guerin: minimum 5-year follow up results. Korean J Urol 2003;44:573-578
8. Park JO, Kim DS, Yoon DK, Cho JH. A long term effects of single 6-week intravesical bcg therapy for the recurrence and progression of stage T1 bladder cancer. Korean J Urol 2000;41:1-7.
9. Palou Redorta J. Management of BCG "Failures". Eur Urol 2006;49:779-780
10. Martin FM, Kamat AM. Definition and management of patients with bladder cancer who fail BCG therapy. Expert Rev Anticancer Ther 2009;9:815-820
11. Klein EA, Rogatko A, Herr HW. Management of local bacillus Calmette-Guerin failures in superficial bladder cancer. J Urol 1992;147:601-605
12. Glashan RW. A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol 1990;144:658-661 (Pubitemid 20296718)
13. Sarosdy MF, Manyak MJ, Sagalowsky AI, Belldegrun A, Benson MC, Bihrle W, et al. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guerin. Urology 1998;51:226-231 (Pubitemid 28093172)
14. O'Donnell MA, Boehle A. Treatment options for BCG failures. World J Urol 2006;24:481-487
15. Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 2003;169:1706-1708 (Pubitemid 36443476)
16. Sengupta S, Blute ML. The management of superficial transitional cell carcinoma of the bladder. Urology 2006;67(3 Suppl 1):48-54. (Pubitemid 43344221)
17. Lamma D, Colombel M, Persad R, Soloway M, Böhle A, Palou J, et al. Clinical practice recommendations for the management of non-muscle invasive bladder cancer. Eur Urol 2008;7(Suppl):651-666
18. Saint F, Salomon L, Quintela R, Cicco A, Hoznek A, Abbou CC, et al. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist?. analysis of a quarter century of literature. Eur Urol 2003;43:351-360 (Pubitemid 36427453)
19. Fernandez-Gomez J, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, Hernandez R, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008;53:992-1001.
20. Kondylis FI, Demirci S, Ladaga L, Kolm P, Schellhammer PF. Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma. J Urol 2000;163:1120-1123 (Pubitemid 30169375)
21. Orsola A, Trias I, Raventós CX, Español I, Cecchini L, Búcar S, et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-nontreated patients. Eur Urol 2005;48:231-238 (Pubitemid 40957095)
22. Orsola A, Cecchini L, Raventós CX, Trilla E, Planas J, Landolfi S, et al. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette- Guérin therapy and the decision for a repeat TUR. BJU Int 2009;Epub ahead of print
23. Saint F, Le Frere Belda MA, Quintela R, Hoznek A, Patard JJ, Bellot J, et al. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG). Eur Urol 2004;45:475-482 (Pubitemid 38376210)
24. Lebret T, Becette V, Hervé JM, Molinié V, Barré P, Lugagne PM, et al. Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette-Guérin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer. Eur Urol 2000;37:654-659 (Pubitemid 30255780)
25. Lacombe L, Dalbagni G, Zhang ZF, Cordon-Cardo C, Fair WR, Herr HW, et al. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome. J Clin Oncol 1996;14:2646-2652 (Pubitemid 26329648)
26. Lebret T, Becette V, Barbagelatta M, Hervé JM, Gaudez F, Barré P, et al. Correlation between p53 over expression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer. J Urol 1998;159:788-791 (Pubitemid 28106526)
27. Zlotta AR, Noel JC, Fayt I, Drowart A, Van Vooren JP, Huygen K, et al. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette- Guerin intravesical therapy. J Urol 1999;161:792-798 (Pubitemid 29422368)
28. Esuvaranathan K, Chiong E, Thamboo TP, Chan YH, Kamaraj R, Mahendran R, et al. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Cancer 2007;109:1097-1105 (Pubitemid 46435388)
29. Palou J, Algaba F, Vera I, Rodriguez O, Villavicencio H, Sanchez-Carbayo M. Protein expression patterns of ezrin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance Bacillus Calmette-Guérin. Eur Urol 2008; Epub ahead of print
30. Thalmann GN, Dewald B, Baggiolini M, Studer UE. Interleukin- 8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression. J Urol 1997;158:1340-1344 (Pubitemid 27391191)
31. Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE. Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol 2000;164:2129-2133 (Pubitemid 30835483)
32. Saint F, Kurth N, Maille P, Vordos D, Hoznek A, Soyeux P, et al. Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Guérin response of superficial bladder cancer during induction course and maintenance therapy. Int J Cancer 2003;107:434-440 (Pubitemid 37266464)
33. Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, et al. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol 2002;167:364-367 (Pubitemid 34024586)
34. Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, et al. T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer. J Urol 2001;166:2142-2147 (Pubitemid 33065239)
35. Kumar A, Dubey D, Bansal P, Mandhani A, Naik S. Urinary interleukin-8 predicts the response of standard and low dose intravesical bacillus Calmette-Guerin (modified Danish 1331 strain) for superficial bladder cancer. J Urol 2002;168:2232-2235
36. Takayama H, Nishimura K, Tsujimura A, Nakai Y, Nakayama M, Aozasa K, et al. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. J Urol 2009;181:1894-1900
37. Ayari C, LaRue H, Hovington H, Decobert M, Harel F, Bergeron A, et al. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. Eur Urol 2009;55:1386-1395
38. Metwalli AR, Kamat AM. Controversial issues and optimal management of stage T1G3 bladder cancer. Expert Rev Anticancer Ther 2006;6:1283-1294
39. Gallagher BL, Joudi FN, Maymí JL, O'Donnell MA. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy. Urology 2008;71:297-301.
40. Raj GV, Herr H, Serio AM, Donat SM, Bochner BH, Vickers AJ, et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 2007;177:1283-1286 (Pubitemid 46435978)
41. Grossman HB, O'Donnell MA, Cookson MS, Greenberg RE, Keane TE. Bacillus Calmette-Guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer. Rev Urol 2008;10:281-289
42. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J Urol 2001;166:1296-1299
43. Mahmud SM, Fong B, Fahmy N, Tanguay S, Aprikian AG. Effect of preoperative delay on survival in patients with bladder cancer undergoing cystectomy in Quebec: a population based study. J Urol 2006;175:78-83. (Pubitemid 41797090)
44. Lamm D. Improving patient outcomes: optimal BCG treatment regimen to prevent progression in superficial bladder cancer. Eur Urol 2006;5(Suppl):654- 659 (Pubitemid 43903409)
45. Bui TT, Schellhammer PF. Additional bacillus Calmette- Guérin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology 1997;49:687-690
46. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168:1964-1970
47. Böhle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal metaanalysis of comparative studies on tumor progression. Urology 2004;63:682-686 (Pubitemid 38479409)
48. Herr HW. Is maintenance bacillus Calmette-Guérin really necessary? Eur Urol 2008;54:971-973
49. Belldegrun AS, Franklin JR, O'Donnell MA, Gomella LG, Klein E, Neri R, et al. Superficial bladder cancer: the role of interferon-alpha. J Urol 1998;159:1793-1801 (Pubitemid 29190700)
50. Portillo J, Martin B, Hernandez R, Correas M, Gutierrez J, Del Valle J, et al. 2: Results at 43 months' follow-up of a doubleblind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. Urology 1997;49:187-190
51. Joudi FN, Smith BJ, O'Donnell MA. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 2006;24: 344-348
52. Bouffioux C, Denis L, Oosterlinck W, Viggiano G, Vergison B, Keuppens F, et al. Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cancer Genitourinary Group. J Urol 1992;148: 297-301.
53. Malmström PU, Wijkström H, Lundholm C, Wester K, Busch C, Norlén BJ. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999;161:1124-1127
54. Witjes JA. Management of BCG failures in superficial bladder cancer: a review. Eur Urol 2006;49:790-797
55. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000;163:761-767 (Pubitemid 30091611)
56. Morabito F, Rossi R, Graziano ME, Ferrando U, Lancini V, Cretarola E, et al. Multicenter study on the use of gemcitabine to prevent recurrence of multiple-recurring superficial bladder tumors following intravesical antiblastic agents and/or BCG: evaluation of tolerance. Arch Ital Urol Androl 2006;78:1-4. (Pubitemid 43736065)
57. Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W, Rabbani F, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin- refractory transitional-cell carcinoma of the bladder. J Clin Oncol 2002;20:3193-3198 (Pubitemid 34831514)
58. Gontero P, Casetta G, Maso G, Sogni F, Pretti G, Zitella A, et al. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 2004;46:339-343 (Pubitemid 39078568)
59. Bartoletti R, Cai T, Gacci M, Giubilei G, Viggiani F, Santelli G, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology 2005;66:726-731 (Pubitemid 41440812)
60. Bassi P, De Marco V, Tavolini IM, Longo F, Pinto F, Zucchetti M, et al. Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy. Urol Int 2005;75:309-313 (Pubitemid 41752577)
61. Gacci M, Bartoletti R, Cai T, Nerozzi S, Pinzi N, Repetti F, et al. Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study. Urol Int 2006;76:106-111 (Pubitemid 43872556)
62. Dalbagni G, Russo P, Bochner B, Ben-Porat L, Sheinfeld J, Sogani P, et al. Phase II trial of intravesical gemcitabine in bacille Calmette- Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 2006;24:2729-2734 (Pubitemid 46630569)
63. McKiernan JM, Masson P, Murphy AM, Goetzl M, Olsson CA, Petrylak DP, et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 2006;24:3075-3080 (Pubitemid 46638943)
64. Barlow L, McKiernan J, Sawczuk I, Benson M. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy. BJU Int 2009;104:1098-1102
65. Maymi JL, Saltsgaver N, O'Donell MA. Intravesical sequential gemcitabine-mitomycin chemotherapy as salvage treatment for patients with refractory superficial bladder cancer. J Urol 2006;175:271, abstract 840.
66. Colombo R, Brausi M, Da Pozzo L, Salonia A, Montorsi F, Scattoni V, et al. Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. a pilot study on marker lesion. Eur Urol 2001;39:95-100. (Pubitemid 32098477)
67. Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, Zampa G, Storti L, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 2006;7: 43-51. (Pubitemid 43025392)
68. Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, et al. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology 2004;63:466-471
69. van der Heijden AG, Kiemeney LA, Gofrit ON, Nativ O, Sidi A, Leib Z, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004;46:65-71. (Pubitemid 38748512)
70. Alfred Witjes J, Hendricksen K, Gofrit O, Risi O, Nativ O. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party. World J Urol 2009;27:319-324
71. Juarranz A, Jaén P, Sanz-Rodríguez F, Cuevas J, González S. Photodynamic therapy of cancer. Basic principles and applications. Clin Transl Oncol 2008;10:148-154
72. Zuluaga MF, Lange N. Combination of photodynamic therapy with anti-cancer agents. Curr Med Chem 2008;15:1655-1673
73. Waidelich R, Stepp H, Baumgartner R, Weninger E, Hofstetter A, Kriegmair M. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol 2001;165:1904-1907
74. Berger AP, Steiner H, Stenzl A, Akkad T, Bartsch G, Holtl L. Photodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center study. Urology 2003;61:338-341
75. Wo JY, Shipley WU, Dahl DM, Coen JJ, Heney NM, Kaufman DS, et al. The results of concurrent chemo- radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary? BJU Int 2009;104: 179-183